Medizone – Making Hospitals Safer and Capitalizing on Product Research

STOCKGURU PROFILE FOR MEDIZONE - CORPORATE WEB SITE

A sterile hospital environment is something you presume will be maintained.  NOT SO FAST.

Friends, family and even you will find yourself in the hospital sooner or later.  You go there to get well but the frightening reality is that surviving that experience is a crucial factor in your treatment.  The hospital itself is becoming an increasing threat to the very patients it intends to treat.  The indisputable statistics can only give you pause and cause for concern.

These statistics have given the United States cause for concern as well.  New state mandated programs are underway to chart these secondary infections from the hospitals and to address them.

This is where Medizone enters the picture.  The grim reality is that hospitals statistically are  making a greater number of patients sicker each year.  This issue is becoming front and center and the statistics indicate it is worsening for a myriad of reasons from physician’s ties as carriers, to writing instruments to the use of less powerful ‘green’ cleaners.

Medizone International has begun its second series of laboratory trials of AsepticSure™ hospital sterilization technology.  The first round of trials using this technology demonstrated bactericidal effects against C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

AsepticSure™ is preparing to enter the decontamination of hospital business and anticipates the completion of the new studies by early July.  Field trials then be initiated in preparation for marketing later this calendar year.

Basis of Demand for AsepticSure™

During the past five years, most states have passed laws requiring hospitals to collect and report infection rates. A handful of states have zeroed in on a particularly dangerous “superbug”–Methicillin-resistant Staphylcoccus aureus, or MRSA–and mandated that hospitals carry out certain MRSA prevention measures. Some of these states require high-risk patients to be screened for MRSA bacteria upon admission.

The effect of these infections on human lives and bottom lines is staggering. Lawmakers hope their efforts will increase knowledge about hospital-acquired infections, jump-start hospitals’ adoption of prevention practices, inform the public about infection rates and decrease costs.

Dr. William Jarvis, who was with the Centers for Disease Control for 23 years and is a leader in hospital-acquired infection control, sees hospital-acquired infections caused by MRSA as a huge problem.

“If you look at health care-associated infections that are caused by multi-drug resistant organisms, MRSA is No. 1,” he says. “MRSA is the one health care-associated infection that is in virtually every hospital in the United States. If you’re going to pick one pathogen to go after, that would be the one.”

Hospital Infections on the Rise and this Means Demand for AsepticSure™ Will Increase

Hospital-acquired infections–also known as health care-associated or nosocomial infections–develop when a patient is being treated in a health care facility for another condition.

In 2002, the estimated 1.7 million cases of hospital-acquired infections led to nearly 100,000 deaths. Treating the infections adds more than $20 billion to health care spending each year, according to the U.S. Department of Health and Human Services. In 2007, treating a hospital-acquired infection cost, on average, $8,832 per patient/per admission.

Another factor of concern to states is the growing resistance of some infections to existing antibiotics. The effectiveness of antibiotics naturally diminishes with regular use, but overuse of the drugs accelerates this process. Drug-resistant bacteria can multiply and spread, and with fewer tools left to fight them, the infections they cause are increasingly difficult to treat.

Compounding the problem is that few new antibiotics are being developed. The rate of new antibiotics approved by the Food and Drug Administration has dropped consistently since 1980. Only about six new drugs are pending approval from the agency.

MRSA, the drug-resistant form of staph, killed more than 18,000 people in 2005–more than the number who died from AIDS. The proportion of staph infections that were resistant to first-line antibiotics has risen from 22 percent in 1997 to more than 60 percent in 2004. And infections caused by other drug-resistant bacteria are also increasing.

Law Makers Step In and Demand for AsepticSure™ Will Follow

Twenty-six states have enacted some form of reporting law, requiring hospitals, and sometimes other health care facilities, to submit infection data to the state or the Centers for Disease Control, and release this information to the public on the Internet. Lawmakers hope this transparency will bring down infection rates in all facilities.

Individual reporting laws differ from state to state. Many vary on which types of infections are to be reported, whether hospitals must disclose infection incidents and where the data are collected. Most states do not require hospitals to report MRSA infections, and few have begun actually reporting the data.

With hospitals now — and for the first time — mandated by law to track these infections the obligation to identify and protect in a proactive manner will increase demand for AsepticSure™.

Canada Tracks Infections Nationwide

Canada has historically tracked these infections.  In coming blogs we can extrapolate the infection rate in Canada to understand the potential for AsepticSure™ in the United States.

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 200,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.